{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:30:16Z","timestamp":1792020616055,"version":"4.4.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK135269"],"award-info":[{"award-number":["R01DK135269"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS134925"],"award-info":[{"award-number":["R01NS134925"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jconrel.2025.02.043","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T03:23:18Z","timestamp":1740367398000},"page":"1005-1016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Long-acting injectable nanoparticle formulation for sustained release of anti-TNF-\u03b1 antibody therapeutic in ulcerative colitis treatment"],"prefix":"10.1016","volume":"380","author":[{"given":"Yicheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanmuhuang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Erb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurun","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin V.","family":"Kammula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Popov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Tinana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin M.","family":"Selaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Quan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.02.043_bb0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/JIR.S65979","article-title":"Inflammatory bowel disease: clinical aspects and treatments","volume":"7","author":"Fakhoury","year":"2014","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","article-title":"Mechanisms of disease: inflammatory bowel diseases","volume":"94","author":"Ramos","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0015","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/gut.29.3.342","article-title":"Symptoms and stool patterns in patients with ulcerative colitis","volume":"29","author":"Rao","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/ncpgasthep0528","article-title":"Mechanisms of disease: pathogenesis of Crohn\u2019s disease and ulcerative colitis","volume":"3","author":"Sartor","year":"2006","journal-title":"Nat. Clin. Pract. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0025","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.mayocp.2014.07.002","article-title":"Ulcerative colitis: epidemiology, diagnosis, and management","volume":"89","author":"Feuerstein","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0030","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0035","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0040","first-page":"1","article-title":"Crohn\u2019s disease","author":"C. Institute","year":"2024","journal-title":"Dis. Rev."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0045","series-title":"Differentiation between Irritable Bowel Syndrome from Inflammatory Bowel Disease flare-up through gut microbiota assessing test in quiescent IBD patients with IBS-like symptoms","author":"Quintana Garcia","year":"2020"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0050","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.3748\/wjg.v17.i37.4166","article-title":"Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease","volume":"17","author":"Bradford","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0055","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1542-3565(04)00344-1","article-title":"Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety","volume":"2","author":"Dubinsky","year":"2004","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1586\/eci.12.91","article-title":"Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update","volume":"9","author":"Denmark","year":"2013","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0065","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114081","article-title":"The treatment of inflammatory bowel disease with monoclonal antibodies in Asia","volume":"157","author":"Chen","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0075","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1053\/j.gastro.2004.11.051","article-title":"Autologous hematopoietic stem cell transplantation in patients with refractory Crohn\u2019s disease","volume":"128","author":"Oyama","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40001-023-01008-7","article-title":"Therapeutic potential of mesenchymal stem\/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy","volume":"28","author":"Saadh","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/apt.13864","article-title":"Mesenchymal stromal cell therapy for inflammatory bowel diseases","volume":"45","author":"Gr\u00e9goire","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000367827","article-title":"Immune cell therapy in IBD","volume":"32","author":"Dunkin","year":"2014","journal-title":"Dig. Dis."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0095","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","article-title":"Targeting immune cell circuits and trafficking in inflammatory bowel disease","volume":"20","author":"Neurath","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0100","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2012.05057.x","article-title":"Systematic review: antibodies and anti-TNF-\u03b1 levels in inflammatory bowel disease","volume":"35","author":"Chaparro","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/ajg.2014.357","article-title":"Treatment of IBD: where we are and where we are going","volume":"110","author":"Bernstein","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","article-title":"Biologic agents for IBD: practical insights","volume":"12","author":"Danese","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0115","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdn054","article-title":"A clinical study assessing the tolerability and biological effects of infliximab, a TNF-\u03b1 inhibitor, in patients with advanced cancer","volume":"19","author":"Brown","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0120","doi-asserted-by":"crossref","first-page":"13799","DOI":"10.1074\/jbc.M112.433961","article-title":"Structural basis for treating tumor necrosis factor \u03b1 (TNF\u03b1)-associated diseases with the therapeutic antibody infliximab","volume":"288","author":"Liang","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0125","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0135","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-\u03b14\u03b27 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0140","first-page":"308","article-title":"Cell death of intestinal epithelial cells in intestinal diseases","volume":"72","author":"Subramanian","year":"2020","journal-title":"Sheng Li Xue Bao [Acta Physiol. Sin.]"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0145","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/intimm\/dxu051","article-title":"Pleiotropic functions of TNF-\u03b1 in the regulation of the intestinal epithelial response to inflammation","volume":"26","author":"Leppkes","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0150","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/imt.10.67","article-title":"Anti-TNF-\u03b1 agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls","volume":"2","author":"Silva","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0155","series-title":"Biological Therapy for Inflammatory Bowel Disease","article-title":"The role of TNF in the pathogenesis of inflammatory bowel disease","author":"Per\u0161e","year":"2019"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0160","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211059954","article-title":"Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues","volume":"14","author":"Peyrin-Biroulet","year":"2021","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1478-6354-13-S1-S2","article-title":"Infliximab: 12 years of experience","volume":"13","author":"Smolen","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0170","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2036.2007.03415.x","article-title":"Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up","volume":"26","author":"Kohn","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0175","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0180","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjw133","article-title":"Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2\/3 PURSUIT induction and maintenance studies","volume":"11","author":"Adedokun","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0185","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/00325481.1989.11704340","article-title":"Life-threatening allergic reactions: anticipating and preparing are the best defenses","volume":"86","author":"Stafford","year":"1989","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0190","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.jaip.2019.02.031","article-title":"Acute management, diagnosis, and follow-up of suspected perioperative hypersensitivity reactions in Flanders 2001-2018","volume":"7","author":"Ebo","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0195","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"New Eng. J. Med."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0200","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41573-023-00670-0","article-title":"Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems","volume":"22","author":"Baryakova","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0205","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1208\/s12248-015-9814-9","article-title":"Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges","volume":"17","author":"Wen","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0210","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.4049\/jimmunol.2001432","article-title":"Local sustained delivery of anti\u2013IL-17A antibodies limits inflammatory bone loss in murine experimental periodontitis","volume":"206","author":"Pacheco","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cis.2018.02.002","article-title":"Encapsulation, protection, and delivery of bioactive proteins and peptides using nanoparticle and microparticle systems: a review","volume":"253","author":"McClements","year":"2018","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0220","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2017.01.067","article-title":"Protein-based nanoparticles: from preparation to encapsulation of active molecules","volume":"522","author":"Tarhini","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0225","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/pharmaceutics16010131","article-title":"Chemistry and art of developing lipid nanoparticles for biologics delivery: focus on development and scale-up","volume":"16","author":"John","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.580118","article-title":"Lipid nanoparticles as carriers for bioactive delivery","volume":"9","author":"Dhiman","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0235","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1039\/C7NR08047F","article-title":"Scalable production of core\u2013shell nanoparticles by flash nanocomplexation to enhance mucosal transport for oral delivery of insulin","volume":"10","author":"He","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0240","doi-asserted-by":"crossref","DOI":"10.4103\/0975-8453.75046","article-title":"Polyelectrolyte complex: a pharmaceutical review","volume":"1","author":"Dakhara","year":"2010","journal-title":"Syst. Rev. Pharm."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0245","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/polym11040578","article-title":"Macro-and microphase separated protein-polyelectrolyte complexes: design parameters and current progress","volume":"11","author":"Horn","year":"2019","journal-title":"Polymers"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0250","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.nantod.2016.04.006","article-title":"Principles of nanoparticle formation by flash nanoprecipitation","volume":"11","author":"Saad","year":"2016","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121244","article-title":"Sustained IGF-1 delivery ameliorates effects of chronic denervation and improves functional recovery after peripheral nerve injury and repair","volume":"280","author":"Hanwright","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0260","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1039\/C9NR09900J","article-title":"Kinetically assembled binary nanoparticle networks","volume":"12","author":"Wang","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0265","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3390\/polym11091406","article-title":"Rapid, single-step protein encapsulation via flash nanoprecipitation","volume":"11","author":"Levit","year":"2019","journal-title":"Polymers"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0270","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jconrel.2021.06.017","article-title":"Challenges and opportunities in the development of complex generic long-acting injectable drug products","volume":"336","author":"O'Brien","year":"2021","journal-title":"J. Control. Rel."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106253","article-title":"Lipid based intramuscular long-acting injectables: current state of the art","volume":"178","author":"Wilkinson","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0280","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nantod.2014.04.008","article-title":"Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects","volume":"9","author":"Barua","year":"2014","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.896591","article-title":"The role of tissue-resident macrophages in the development and treatment of inflammatory bowel disease","volume":"10","author":"Ma","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0290","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2016.03.041","article-title":"The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension","volume":"230","author":"Darville","year":"2016","journal-title":"J. Controll. Rel."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0295","article-title":"A nanofiber-hydrogel composite improves tissue repair in a rat model of Crohn\u2019s disease perianal fistulas","volume":"9","author":"Li","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0300","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejpb.2013.10.013","article-title":"Encapsulation of immunoglobulin G by solid-in-oil-in-water: effect of process parameters on microsphere properties","volume":"86","author":"Marquette","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0305","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1208\/s12249-021-02074-y","article-title":"Solid-in-oil-in-water emulsion: an innovative paradigm to improve drug stability and biological activity","volume":"22","author":"Sawant","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0310","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcis.2003.08.072","article-title":"Stabilization and encapsulation of human immunoglobulin G into biodegradable microspheres","volume":"271","author":"Wang","year":"2004","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0315","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s42452-021-04609-1","article-title":"Quality by design prospects of pharmaceuticals application of double emulsion method for PLGA loaded nanoparticles","volume":"3","author":"Panigrahi","year":"2021","journal-title":"SN Appl. Sci."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0320","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11051-008-9446-4","article-title":"Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies","volume":"11","author":"Jiang","year":"2009","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0325","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1021\/acs.chemrev.7b00208","article-title":"Stability and reactivity: positive and negative aspects for nanoparticle processing","volume":"118","author":"Xu","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0330","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13045-021-01150-x","article-title":"Intracellular delivery of anti-BCR\/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0335","doi-asserted-by":"crossref","first-page":"14188","DOI":"10.1038\/s41598-020-71129-0","article-title":"Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized\/targeted drug delivery on the treatment of triple-negative breast cancer","volume":"10","author":"Jusu","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0340","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40005-022-00584-w","article-title":"Controlled release and targeted drug delivery with poly(lactic-co-glycolic acid) nanoparticles: reviewing two decades of research","volume":"52","author":"Zeb","year":"2022","journal-title":"J. Pharm. Invest."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0345","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3389\/fimmu.2019.00526","article-title":"An anti-hTNF-\u03b1 variable new antigen receptor format demonstrates superior in vivo preclinical efficacy to Humira\u00ae in a transgenic mouse autoimmune polyarthritis disease model","volume":"10","author":"Ubah","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0350","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/pharmaceutics12060539","article-title":"Review: local tumor necrosis factor-\u03b1 inhibition in inflammatory bowel disease","volume":"12","author":"Gareb","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0355","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4049\/jimmunol.2101180","article-title":"An engineered monovalent anti\u2013TNF-\u03b1 antibody with ph-sensitive binding abrogates immunogenicity in mice following a single intravenous dose","volume":"209","author":"Watkins","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0360","doi-asserted-by":"crossref","first-page":"1273280","DOI":"10.3389\/fimmu.2024.1273280","article-title":"Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins","volume":"15","author":"Daurat","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0365","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10787-014-0207-y","article-title":"Animal models of inflammatory bowel disease: a review","volume":"22","author":"Goyal","year":"2014","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0370","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nprot.2007.41","article-title":"Chemically induced mouse models of intestinal inflammation","volume":"2","author":"Wirtz","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0375","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/gut.2009.197822","article-title":"Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome","volume":"59","author":"Bauer","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0380","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/ibd\/izad312","article-title":"Unveiling colitis: a journey through the dextran sodium sulfate-induced model","volume":"30","author":"Yang","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0385","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/01.TP.0000114872.26990.4F","article-title":"Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets","volume":"77","author":"Goto","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0390","doi-asserted-by":"crossref","first-page":"15.25.11","DOI":"10.1002\/0471142735.im1525s104","article-title":"Dextran sulfate sodium (DSS)-induced colitis in mice","volume":"104","author":"Chassaing","year":"2014","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42826-021-00084-2","article-title":"Inflammatory responses of C57BL\/6NKorl mice to dextran sulfate sodium-induced colitis: comparison between three C57BL\/6 N sub-strains","volume":"37","author":"Kim","year":"2021","journal-title":"Lab. Anim. Res."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0400","article-title":"BAFF blockade attenuates DSS-induced chronic colitis via inhibiting NLRP3 inflammasome and NF-\u03baB activation","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0405","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1075114","article-title":"Repeated PD-1\/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer","volume":"5","author":"Mall","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12090852","article-title":"Acute and chronic dosing of a high-affinity rat\/mouse chimeric transferrin receptor antibody in mice","volume":"12","author":"Castellanos","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0415","series-title":"Therapeutic Antibodies","first-page":"101","article-title":"Anti-TNF antibodies: Lessons from the past, roadmap for the future","author":"Shealy","year":"2008"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0420","article-title":"The Mayo endoscopic score is a novel predictive indicator for malignant transformation in ulcerative colitis: a long-term follow-up multicenter study","volume":"9","author":"Xu","year":"2022","journal-title":"Front. Surg."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0425","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/gastroent12020019","article-title":"Mayo endoscopic score and ulcerative colitis endoscopic index are equally effective for endoscopic activity evaluation in ulcerative colitis patients in a real life setting","volume":"12","author":"Pagnini","year":"2021","journal-title":"Gastroenterol. Insights"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-9255-2-13","article-title":"Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector","volume":"2","author":"Sasaki","year":"2005","journal-title":"J. Inflamm."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0435","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ibd.20753","article-title":"Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis","volume":"15","author":"Alex","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0440","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00428-013-1474-5","article-title":"Lymphoid aggregates in Crohn\u2019s colitis and mucosal immunity","volume":"463","author":"Rubio","year":"2013","journal-title":"Virchows Arch."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0445","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/gutjnl-2012-303955","article-title":"Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation","volume":"62","author":"Cader","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2025.02.043_bb0450","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.3390\/cimb45040189","article-title":"Infliximab inhibits colitis associated cancer in model mice by downregulating genes associated with mast cells and decreasing their accumulation","volume":"45","author":"Wang","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.jconrel.2025.02.043_bb0455","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4049\/jimmunol.168.1.57","article-title":"Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine","volume":"168","author":"Hamada","year":"2002","journal-title":"J. Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925001567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925001567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:48:43Z","timestamp":1770140923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925001567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":91,"alternative-id":["S0168365925001567"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.02.043","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-acting injectable nanoparticle formulation for sustained release of anti-TNF-\u03b1 antibody therapeutic in ulcerative colitis treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.02.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}